Advertisement

Topics

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects

2014-10-03 16:35:29 | BioPortfolio

Published on BioPortfolio: 2014-10-03T16:35:29-0400

Clinical Trials [908 Associated Clinical Trials listed on BioPortfolio]

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

This study will evaluate longitudinal change of tau deposition as measured by 18F-AV-1451 uptake over time.

18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

18F-AV-1451 Autopsy Study

This study is designed to test the relationship between ante-mortem 18F-AV-1451 Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's dis...

Clinical Evaluation of 18F-AV-1451

This study is designed to expand the database of 18F-AV-1451 safety and tau binding as measured by PET imaging and to provide standardized conditions for 18F-AV-1451 use, data collection a...

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol)...

PubMed Articles [14881 Associated PubMed Articles listed on BioPortfolio]

The Added Value of Dynamic 18F-Florbetapir PET in the Assessment of Dementia With Lewy Bodies.

Dementia with Lewy bodies (DLB) is the most common cause of dementia after Alzheimer disease. It is often underdiagnosed because of the overlapping with Alzheimer disease symptoms. We report the F-FDG...

The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.

Lilly/Avid's AV-1451 is one of the most advanced tau PET tracers in the clinic. Although results obtained in Alzheimer's disease patients are compelling, discrimination of tracer uptake in healthy ind...

Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.

We examined the relationship between in vivo estimates of tau deposition as measured byF-AV-1451 tau positron emission tomography imaging and cross-sectional cortical thickness, as well as rates of a...

Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.

Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear.

Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study.

Exploring the role of Alzheimer's disease (AD) implicated pathways in the predementia phase may provide new insight for preventive and clinical trials targeting disease specific pathways.

Medical and Biotech [MESH] Definitions

The period of history from 1451 through 1600 of the common era.

Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.

Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.

A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

More From BioPortfolio on "Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial